Loading…
Based on limited metadata, Surmasis Pharmaceutical received an FDA Warning Letter on November 6, 2018 regarding drug products. While the specific violations cannot be detailed without access to the full letter text, the warning indicates regulatory concerns significant enough to warrant formal FDA action. The letter was issued under FDA's drug regulatory authority, though the specific issuing office and exact violation count are not available in this metadata summary.